Seattle-based biotech company HDT Bio closed a seed round totaling roughly $3 million to support work on its COVID-19 vaccine candidate HDT-301.

Researchers from HDT Bio and the University of Washington in July published a rapid-release paper in the

https://contacted.org/2020/10/seattle-startup-hdt-bio-raises-3m-to-support-development-of-covid-19-vaccine/